Analysts Set OptimizeRx Co. (NASDAQ:OPRX) Target Price at $10.42

Shares of OptimizeRx Co. (NASDAQ:OPRX) have been assigned an average recommendation of “Moderate Buy” from the seven research firms that are currently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $10.42.

Several equities research analysts recently weighed in on the company. William Blair reaffirmed an “outperform” rating on shares of OptimizeRx in a research note on Thursday, November 14th. Stifel Nicolaus dropped their price objective on shares of OptimizeRx from $13.00 to $8.00 and set a “buy” rating on the stock in a research note on Thursday, November 14th. Roth Mkm reiterated a “buy” rating and set a $16.00 target price (down from $20.00) on shares of OptimizeRx in a report on Thursday, November 14th. JMP Securities cut their price target on OptimizeRx from $16.00 to $8.00 and set a “market outperform” rating on the stock in a research note on Thursday, November 14th. Finally, Barclays lowered their price objective on OptimizeRx from $11.00 to $5.00 and set an “equal weight” rating for the company in a research note on Thursday, November 14th.

Hedge Funds Weigh In On OptimizeRx

Hedge funds have recently added to or reduced their stakes in the company. Rice Hall James & Associates LLC increased its holdings in shares of OptimizeRx by 24.0% in the 3rd quarter. Rice Hall James & Associates LLC now owns 615,441 shares of the company’s stock worth $4,751,000 after purchasing an additional 119,306 shares in the last quarter. Janney Montgomery Scott LLC bought a new stake in OptimizeRx in the 3rd quarter worth about $810,000. First Light Asset Management LLC raised its position in OptimizeRx by 5.1% in the 2nd quarter. First Light Asset Management LLC now owns 1,826,961 shares of the company’s stock worth $18,270,000 after buying an additional 89,377 shares during the last quarter. Bullseye Asset Management LLC lifted its stake in OptimizeRx by 55.6% during the 3rd quarter. Bullseye Asset Management LLC now owns 214,046 shares of the company’s stock valued at $1,652,000 after acquiring an additional 76,458 shares during the period. Finally, Essex Investment Management Co. LLC boosted its holdings in shares of OptimizeRx by 42.9% during the 3rd quarter. Essex Investment Management Co. LLC now owns 242,025 shares of the company’s stock valued at $1,868,000 after acquiring an additional 72,672 shares during the last quarter. 76.47% of the stock is currently owned by hedge funds and other institutional investors.

OptimizeRx Trading Down 10.0 %

NASDAQ:OPRX opened at $4.95 on Monday. OptimizeRx has a 12 month low of $3.78 and a 12 month high of $16.65. The company has a 50-day moving average price of $5.66 and a 200-day moving average price of $8.15. The company has a current ratio of 3.23, a quick ratio of 3.23 and a debt-to-equity ratio of 0.29. The stock has a market cap of $91.18 million, a price-to-earnings ratio of -3.72 and a beta of 1.34.

OptimizeRx Company Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.